News – Page 30 – Endpoints News

Ahead of FDA decision, Alnylam faces the big question: Can it make money?

2 months ago

Regenxbio shares new Duchenne gene therapy data ahead of big readout next year

2 months ago

Pfizer fully exits Sensodyne maker Haleon in $3.3B stake sale

2 months ago

Updated: Immunovant will not take rare disease drug to regulators despite Phase 3 win

2 months ago

Roche inks $1B+ biobucks deal with UK biotech for new antibody cancer targets

2 months ago

Flagship's Ampersand gets Eli Lilly's support in $65M Series B

2 months ago

Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drug

2 months ago

Stem cell company bit.bio cuts quarter of staff, drops therapeutics focus

2 months ago

HHS keeps probationary workers on administrative leave after court order

2 months ago

Empress Therapeutics confirms layoffs; Nanobiotix amends J&J deal terms

2 months ago

Stoke CEO Ed Kaye to depart shortly after inking Biogen pact and before its first Phase 3 trial

2 months ago

Sixteen-year-old dies after receiving Sarepta’s Duchenne gene therapy

2 months ago

Exclusive: Foodsmart names former Amwell executive as its new CEO

2 months ago

A Japanese biotech founded by Treg cell discoverer moves to the US with $45.8M

2 months ago

Updated: Novartis revamps cardiovascular commercial strategy as Entresto patent cliff looms

2 months ago

CRISPR company Arbor raises $73.9M to test therapy in clinical trials

2 months ago

Sofinnova Partners lands €165M, backed by big pharma, to build early-stage biotechs in Europe

2 months ago

FDA staff return to White Oak campus en masse after Trump administration push

2 months ago

Trump’s HHS defends Biden-era stance on 340B rebate models

2 months ago

AstraZeneca taps Alteogen in deal worth more than $1.3B to make subcutaneous cancer drugs

2 months ago

WuXi AppTec's US revenue growth continues to dip in post-Biosecure environment

2 months ago

AstraZeneca reports Phase 3 success for rare disease drug at heart of Amolyt deal

2 months ago

All selected drugmakers agree to second round of price negotiations under the IRA

2 months ago

Incyte's stock sinks as pivotal skin disease data disappoint

2 months ago

First page Previous page 27 28 293031 32 33 Next page Last page